Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174

Clinical Pharmacology and Therapeutics

Volumn 65, Issue 3, 1999, Pages 348-352

  McCrea, Jacqueline B ^a   Cribb, Alastair ^b   Rushmore, Tom ^b   Osborne, Barbara ^b   Gillen, Lisa ^b   Lo, Man Wai ^b   Waldman, Scott ^b   Bjornsson, Thorir ^b   Spielberg, Stephen ^b   Goldberg, Michael R ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; CARBOXYTOLBUTAMIDE; CYTOCHROME P450; DAPSONE; DRUG METABOLITE; ERYTHROMYCIN; HYDROXYTOLBUTAMIDE; LOSARTAN; N HYDROXYDAPSONE; PHENYTOIN; TOLBUTAMIDE; WARFARIN;

ADULT; ARTICLE; BREATH ANALYSIS; CASE REPORT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG METABOLISM; DRUG OXIDATION; DRUG URINE LEVEL; ENZYME ACTIVITY; GENE AMPLIFICATION; GENOTYPE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0033040522     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70114-1     Document Type: Article

References (28)

1. 1. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995;58:641-9.
2. 2. Cozaar. In: Physicians' desk reference. 52nd ed. Montvale (NJ): Medical Economics; 1998.
3. 3. Goldberg MR, Lo MW, Deutsch P, Wilson S, McWilliam E, McCrea J. Phenobarb minimally alters plasma concentrations of losartan and its active metabolite E-3174. Clin Pharmacol Ther 1996;59:268-74.
4. 4. Stearns RA, Chakravarty PK, Chen R, Chiu SHL. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Drug Metab Dispos 1995;23:207-15.
5. 5. Yun CH, Lee HS, Lee H, Rho JK, Jeong HG, Guengerich P. Oxidation of the angiotensin II receptor antagonist losartan (DUP 735) in human liver microsomes. Drug Metab Dispos 1995;23:285-9.
6. 6. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P450. J Clin Invest 1989;83:688-97.
7. 7. May DG, Anns PA, Richards WO, Porter J, Ryder D, Fleming CM, et al. The disposition of dapsone in cirrhosis. Clin Pharmacol Ther 1992;51:689-700.
8. 8. Veronese M, Miners J, Randles D, Gregov D, Birkett D. Validation of the tolbutamide metabolic ratio for population screening with use of sulphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther 1990;47:403-11.
9. 9. Keal J, Stockley C, Somogyi A. Simultaneous determination of tolbutamide and its hydroxy and carboxy metabolites in plasma and urine by high performance liquid chromatography. J Chromatogr 1986;378:237-41.
10. 10. Vermeij P, Ferrari MD, Burma OJS, Veenema H, de Wolff FA. Inheritance of poor phenytoin hydroxylation capacity in a Dutch family. Clin Pharmacol Ther 1988;44:588-93.
11. 11. Dickinson RG, Hooper WD, Patterson M, Eadie MJ, Maguire B. Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin. Ther Drug Monit 1993;7:283-9.
12. 12. May DG, Porter J, Wilkinson GR, Branch RA. Frequency distribution of dapsone N-hydroxylation, a putative probe for P4503A4 activity in a white population. Clin Pharmacol Ther 1994;55:492-500.
13. 13. Veronese ME, Miners JO, Rees DLP, Birkett DJ. Tolbutamide hydroxylation in humans: lack of bimodality in 106 healthy subjects. Pharmacogenetics 1993;3:86-93.
14. 14. Glazko AJ, Peterson FE, Chang T, Dill WA, Smith TC, Buchanan RA. Phenytoin metabolism in subjects with long and short plasma half-lives. Ther Drug Monit 1982;4:281-92.
15. 15. Peeters EAJ, Bloem BR, Kuiper MA, Vermeij P, de Wolff FA, Wolters EC, et al. Phenytoin parahydroxylation is not impaired in patients with young-onset Parkinson's disease. Clin Neurol Neurosurg 1994;96:296-9.
16. 16. Guengerich P. Human cytochrome P-450 enzymes. Life Sci 1992;50:1471-8.
17. 17. Watkins PB. Noninvasive test of CYP3A4 enzymes. Pharmacogenetics 1994;4:171-84.
18. 18. Kinirons MT, O'Shea D, Downing TE, Fitzwilliam AT, Joellenbeck L, Groupman JD, et al. Absence of correlalions among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 1993;54:621-9.
19. 19. Mitra AK, Thummel KE, Kalhorn TF, Kharasch ED, Unadkat JD, Slattery JT. Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. Clin Pharmacol Ther 1995;58:556-66.
20. 20. McCrea JB, Lo MW, Furtek CT, Ritter MA, Carides A, Waldman SA, et al. Ketoconazole does not effect the systemic conversion of losartan to E-3174 [abstract]. Clin Pharmacol Ther 1996; 169.
21. 21. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 1991;174:1112-8.
22. 22. Tassaneeyakul W, Veronese ME, Birkett DJ, Doecke CJ, McManus ME, Sansom LN, and Miners OJ. Co-regulation of phenytoin and tolbutamide metabolism in humans. Br J Clin Pharmacol 1992;34:494-8.
23. 23. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994;33:1743-52.
24. 24. Veronese ME, Doecke CJ, Mackenzie PI, McManus ME, Miners JO, Rees DLP, et al. Site directed mutation studies of human liver cytochrome P-450 isozymes in the CYP2C subfamily. Biochem J 1993;289:533-8.
25. 25. Rettie A, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalyzed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994;4:39-42.
26. 26. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996;6:341-9.
27. 27. Odani A, Hashimoto Y, Otsuki Y, Uwai Y Hattori H, Furosho K, et al. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther 1997;62:287-92.
28. 28. Ikeda L, Harm SC, Arcuri KE, Goldberg AI, Sweet CS. Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension. Blood Press 1997;6:35-43.